Top News

American Apparel Got Indication of Interest for $1.30-$1.40 per Share
Tweet TWEET

ResearchMoz: Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease,

  ResearchMoz: Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only
Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other
               Late Stage Trials Fail - Market Research Report

  PR Newswire

  ALBANY, New York, January 9, 2013

ALBANY, New York, January 9, 2013 /PRNewswire/ --

New Report Added in ResearchMoz Reports Database Liver Cancer Therapeutics
Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced
Disease, Continues to Dominate as Other Late Stage Trials Fail

ResearchMoz announces that it has published a new study Liver Cancer
Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for
Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail .
Leading business intelligence provider, GBI Research, has released its latest
research report, entitled: "Liver Cancer Therapeutics Market to 2018 -
Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to
Dominate as Other Late Stage Trials Fail". The report provides insights into
the liver cancer therapeutics market in the US, the top five European
countries (the UK, Germany, France, Italy and Spain) and Japan, with market
forecasts until 2018. It provides in-depth analysis of the major marketed
products, as well as insights into the liver cancer therapeutics R&D pipeline.
The report also gives in-depth analysis of the unmet needs, drivers and
barriers that affect the markets in these countries. Additionally, it
discusses the global pipeline for all the liver cancer molecules across
various stages of development.

To Browse Full TOC, Tables & Figures visit: 
http://www.researchmoz.us/liver-cancer-therapeutics-market-to-2018-nexavar-the-only-approved-targeted-therapy-for-advanced-disease-continues-to-dominate-as-other-late-stage-trials-fail-report.html


The report is built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by GBI
Research's team of industry experts.

GBI Research found that the liver cancer therapeutics in the top seven markets
(the US, the UK, Germany, France, Spain, Italy and Japan) was estimated at
$374.3m in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 21.7%
from 2004. Growth was driven by an increase in the patient volume and the
Annual Cost of Therapy (ACT) per patient, which increased due to the approval
of Nexavar (sorafenib) in the US and Europe. The market is forecast to reach
revenues of $644.3m by 2018, growing at a CAGR of 8.1% from 2011.

Related Reports @ http://www.researchmoz.us/liver-cancer.htm 

Liver Cancer Global Clinical Trials Review

Chinese Markets for Liver Cancer Treatment Drugs

China Optical Communication Industry

Global and China Toy Industry

China Copper Processing Material Industry

China Diagnostic Reagent Industry

China Solid Waste Disposal Industry

China OLED Industry

China's Diabetes Drug Market

Batteries and Supercapacitors for the Smart Grid

The current competition in the liver cancer market is weak, as Nexavar is the
only drug approved for advanced Hepatocellular Carcinoma (HCC) with the
exception of Miripla (miriplatin) in Japan. However, there are some molecules
in Phase III development as first-line and second-line treatments which
promise to influence the competitive landscape in the next two to three years.
The anticipated launch of Eli Lilly's ramucirumab (IMC-1121B), a monoclonal
antibody in 2014; Celsion Corporation's ThermoDox in 2014; and PrevOnco in
2015 will drive the market forward.

Scope

  *Annualized market data for the liver cancer therapeutics market from 2004
    to 2011 and forecast to 2018
  *Analysis of the liver cancer therapeutics market in the leading
    geographies of the world: the US, the UK, Germany, France, Italy, Spain,
    and Japan
  *Market characterization of the liver cancer therapeutics market including
    market size, annual cost of therapy and treatment usage patterns
  *Key drivers and barriers that affect the market
  *Coverage of pipeline molecules in various Phases of drug development
  *Competitive benchmarking of leading companies including Bayer and
    Dainippon Sumitomo Pharma
  *Key M&A activities and licensing agreements that have taken place between
    2008 and October 2012 in liver cancer therapeutics in the top seven
    markets

Reasons to buy

  *Align your product portfolio to the markets with high growth potential
  *Develop market-entry and market-expansion strategies by identifying the
    regions and market segments poised for strong growth
  *Create a more tailored country strategy through the understanding of key
    drivers and barriers of the liver cancer therapeutics market
  *Develop key strategic initiatives by understanding the key focus areas and
    top-selling products of leading companies
  *Accelerate and strengthen your market position by identifying key
    companies for mergers, acquisitions and strategic partnerships

Latest Reports by GBI Research

Opioids Market

Rheumatology Therapeutics Market

Caprolactam Market

Ethylene Vinyl Acetate (EVA) Global Market

Innovation in the Prefilled Syringe Market

Generic Growth Strategies - Market

Stem Cell Therapy Market in Asia-Pacific

Mobile Health (mHealth) - Enhancing Healthcare

Spinal Surgery Devices Market

Ethylbenzene Global Market

About Us

ResearchMoz is the one stop online destination to find and buy market research
reports & Industry Analysis. We fulfill all your research needs spanning
across industry verticals with our huge collection of market research reports.
We provide our services to all sizes of organizations and across all industry
verticals and markets. Our Research Coordinators have in-depth knowledge of
reports as well as publishers and will assist you in making an informed
decision by giving you unbiased and deep insights on which reports will
satisfy your needs at the best price.

Contact M/s Sheela 90 Sate Street, Suite 700Albany, NY 12207 Tel:
+1-518-618-1030USA - Canada Toll Free: 866-997-4948 Email : 
sales@researchmoz.com http://www.researchmoz.us/  http://www.pdfmoz.com/ 
http://researchmoz.blogspot.kr/ http://www.marketresearch.name/ 
 
Press spacebar to pause and continue. Press esc to stop.